Frederick Kolling

Dr. Frederick Kolling

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JHJichang Han
Jichang Han
YZYanding Zhao
Yanding Zhao
KSKeisuke Shirai
Keisuke Shirai
AMAleksey Molodtsov
Aleksey Molodtsov
FKFrederick Kolling
Frederick Kolling
CAChristina V. Angeles
Christina V. Angeles

22 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KRKavita Rawat
Kavita Rawat
ATAnita Tewari
Anita Tewari
XLXin Li
Xin Li
AMArlind Mara
Arlind Mara
WKWilliam T. King
William T. King
CJClaudia V. Jakubzick
Claudia V. Jakubzick
Dendritic cells (DCs) and monocytes capture, transport, and present antigen to cognate T cells in the draining lymph nodes (LNs) in a CCR7-dependent manner. Since only migratory DCs express this chemokine receptor, it is unclear how monocytes reach the LN. In steady-state and following inhalation of several PAMPs, scRNA-seq identified LN mononuclear phagocytes as monocytes, resident, or migratory type 1 and type 2 conventional (c)DCs, despite the downregulation of Xcr1, Clec9a, H2-Ab1, Sirpa, and Clec10a transcripts on migratory cDCs. Migratory cDCs, however, upregulated Ccr7, Ccl17, Ccl22, and Ccl5. Migratory monocytes expressed Ccr5, a high-affinity receptor for Ccl5. Using two tracking methods, we observed that both CD88hiCD26lomonocytes and CD88−CD26hi cDCs captured inhaled antigens in the lung and migrated to LNs. Antigen exposure in mixed-chimeric Ccl5-, Ccr2-, Ccr5-, Ccr7-, and Batf3-deficient mice demonstrated that while antigen-bearing DCs use CCR7 to reach the LN, monocytes use CCR5 to follow CCL5-secreting migratory cDCs into the LN, where they regulate DC-mediated immunity.

2 May 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
XLXin Li
Xin Li
AMArlind Mara
Arlind Mara
SMShawn C. Musial
Shawn C. Musial
FKFrederick Kolling
Frederick Kolling
SGSophie L. Gibbings
Sophie L. Gibbings
CJClaudia V. Jakubzick
Claudia V. Jakubzick

6 July 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KKKatja Koeppen
Katja Koeppen
ANAmanda Nymon
Amanda Nymon
RBRoxanna Barnaby
Roxanna Barnaby
LBLaura Bashor
Laura Bashor
ZLZhongyou Li
Zhongyou Li
BSBruce Stanton
Bruce Stanton
Significance: Pseudomonas aeruginosa is one of the leading causes of hospital-acquired infections worldwide primarily due to its ability to develop antibiotic-resistant biofilms. This report describes a mechanism whereby human airway epithelial cells (AECs) increase the ability of antibiotics to kill P. aeruginosa and reduce the formation of drug-resistant biofilms. We demonstrate that human AECs secrete extracellular vesicles containing the microRNA let-7b-5p, that the vesicles deliver let-7b-5p to P. aeruginosa , and that let-7b-5p decreases biofilm formation and increases the ability of beta-lactam antibiotics to reduce biofilm formation by down-regulating key antibiotic-resistance and biofilm genes. A combination of let-7b, which is in clinical trials as an anti-inflammatory agent, and beta-lactam antibiotics may help combat antibiotic-resistant P. aeruginosa infections.

8 January 2025 in Cancer Research
Verified
Journal Article
Closed access
STSteven Tau
Steven Tau
MCMary D. Chamberlin
Mary D. Chamberlin
HYHuijuan Yang
Huijuan Yang
JMJonathan D. Marotti
Jonathan D. Marotti
PMPatricia C. Muskus
Patricia C. Muskus
TMTodd W Miller
Todd W Miller
Despite adjuvant treatment with endocrine therapies, estrogen receptor–positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such persister cells may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening in ER+ breast cancer cells, we identified a survival mechanism involving metabolic reprogramming with reliance upon mitochondrial respiration in endocrine-tolerant persister cells. Quantitative proteomic profiling showed reduced levels of glycolytic proteins in persisters. Metabolic tracing of glucose revealed an energy-depleted state in persisters, in which oxidative phosphorylation was required to generate ATP. A phase II clinical trial was conducted to evaluate changes in mitochondrial markers in primary ER+/HER2– breast tumors induced by neoadjuvant endocrine therapy (NCT04568616). In an analysis of tumor specimens from 32 patients, tumors exhibiting residual cell proliferation after aromatase inhibitor–induced estrogen deprivation with letrozole showed increased mitochondrial content. Genetic profiling and barcode lineage tracing showed that endocrine-tolerant persistence occurred stochastically without genetic predisposition. Pharmacologic inhibition of mitochondrial complex I suppressed the tumor-forming potential of persisters in mice and synergized with the antiestrogen drug fulvestrant to induce regression of patient-derived xenografts. These findings indicate that mitochondrial metabolism is essential in endocrine-tolerant persister ER+ breast cancer cells and warrant the development of treatment strategies to leverage this vulnerability for treating breast cancer. Significance: Persister cancer cells that survive endocrine therapy exhibit increased energetic dependence upon mitochondria for survival and tumor regrowth potential, indicating that therapies targeting this metabolic dependency could help prevent disease recurrence.

8 September 2023 in Cells
Verified
Journal Article
Open access
PDF file
ELEdgar Guillermo Valdivia Lara
Edgar Guillermo Valdivia Lara
DADaniel Alonso-Miguel
Daniel Alonso-Miguel
MPMaría Dolores Pérez-Alenza
María Dolores Pérez-Alenza
AZAnna Barbara Emilia Zimmermann
Anna Barbara Emilia Zimmermann
ESEvelien Schaafsma
Evelien Schaafsma
Hugo Arias-PulidoHugo Arias-Pulido
Hugo Arias-Pulido
The lack of optimal models to evaluate novel agents is delaying the development of effective immunotherapies against human breast cancer (BC). In this prospective open label study, we applied neoadjuvant intratumoral immunotherapy with empty cowpea mosaic virus-like particles (eCPMV) to 11 companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. We found that two neoadjuvant intratumoral eCPMV injections resulted in tumor reduction in injected tumors in all patients and in noninjected tumors located in the ipsilateral and contralateral mammary chains of injected dogs. Tumor reduction was independent of clinical stage, tumor size, histopathologic grade, and tumor molecular subtype. RNA-seq-based analysis of injected tumors indicated a decrease in DNA replication activity and an increase in activated dendritic cell infiltration in the tumor microenvironment. Immunohistochemistry analysis demonstrated significant intratumoral increases in neutrophils, T and B lymphocytes, and plasma cells. eCPMV intratumoral immunotherapy demonstrated antitumor efficacy without any adverse effects. This novel immunotherapy has the potential for improving outcomes for human BC patients.